ARYx Therapeutics (ARYx Therapeutics) Accounts Receivable : $0.00 Mil (As of Sep. 2010)

View and export this data going back to 2007. Start your Free Trial

What is ARYx Therapeutics Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. ARYx Therapeutics's accounts receivables for the quarter that ended in Sep. 2010 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. ARYx Therapeutics's Net-Net Working Capital per share for the quarter that ended in Sep. 2010 was $-0.32.

ARYx Therapeutics Accounts Receivable Historical Data

The historical data trend for ARYx Therapeutics's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARYx Therapeutics Accounts Receivable Chart

ARYx Therapeutics Annual Data

Trend

Dec03

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Accounts Receivable

Get a 7-Day Free Trial

ARYx Therapeutics Quarterly Data
	Dec05	Mar06	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10
Accounts Receivable	Get a 7-Day Free Trial															-	-	-	-	-

ARYx Therapeutics Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

ARYx Therapeutics Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

ARYx Therapeutics's Days Sales Outstanding for the quarter that ended in Sep. 2010 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), ARYx Therapeutics's accounts receivable are only considered to be worth 75% of book value:

ARYx Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2010 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(2.954	+	0.75 * 0	+	0.5 * 0	-	13.707
-	0	-	0)	/	33.462
=	-0.32

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

ARYx Therapeutics Accounts Receivable Related Terms

Thank you for viewing the detailed overview of ARYx Therapeutics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

ARYx Therapeutics (ARYx Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ARYx Therapeutics Inc (OTCPK:ARYX) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

6300 Dumbarton Circle, Fremont, CA, USA, 94555

Website

http://www.aryx.com

ARYx Therapeutics Inc is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates designed to eliminate known safety issues associated with well-established, commercially successful drugs.

Executives

Newhall Charles W Iii	10 percent owner	1119 ST PAUL ST, BALTIMORE MD 21202
C Richard Kramlich	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Ryan D Drant	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Krishna Kittu Kolluri	10 percent owner
New Enterprise Associates 12, Limited Partnership	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea Partners 12, Limited Partnership	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea 12 Gp, Llc	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Mark W Perry	10 percent owner
Patrick J Kerins	10 percent owner
Forest Baskett	10 percent owner
Growth Equity Opportunities Fund, Llc	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Peter J Barris	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
M James Barrett	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Scott D Sandell	10 percent owner
Nicholas Galakatos	10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116

ARYx Therapeutics (ARYx Therapeutics) Headlines

No Headlines